NOXO1

Summary

NOXO1 (NADPH oxidase organizer 1, HGNC:19404) is a protein-coding gene on chromosome 16p13.3, encoding NADPH oxidase organizer 1 (Q8NFA2). Constitutively potentiates the superoxide-generating activity of NOX1 and NOX3 and is required for the biogenesis of otoconia/otolith, which are crystalline structures of the inner ear involved in the perception of gravity.

This gene encodes an NADPH oxidase (NOX) organizer, which positively regulates NOX1 and NOX3. The protein contains a PX domain and two SH3 domains. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 124056 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 99 total
• Druggable target: yes
• MANE Select transcript: NM_172167

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19404
Approved symbol	NOXO1
Name	NADPH oxidase organizer 1
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	P41NOXA, P41NOXB, P41NOXC, SH3PXD5, SNX28
Ensembl gene	ENSG00000196408
Ensembl biotype	protein_coding
OMIM	611256
Entrez	124056

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 9 protein_coding, 2 retained_intron

ENST00000354249, ENST00000356120, ENST00000397280, ENST00000563181, ENST00000566005, ENST00000567471, ENST00000569739, ENST00000862125, ENST00000862126, ENST00000862127, ENST00000862128

RefSeq mRNA: 4 — MANE Select: NM_172167 NM_001267721, NM_144603, NM_172167, NM_172168

CCDS: CCDS10454, CCDS10455, CCDS42101, CCDS58406

Canonical transcript exons

ENST00000356120 — 8 exons

Exon	Start	End
ENSE00001062267	1980367	1980544
ENSE00001062268	1979997	1980181
ENSE00001062269	1979790	1979903
ENSE00001062271	1979425	1979542
ENSE00001062274	1980939	1981019
ENSE00001381372	1980656	1980731
ENSE00001901797	1981114	1981469
ENSE00003517317	1978917	1979349

Expression profiles

Bgee: expression breadth ubiquitous, 149 present calls, max score 92.30.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1131 / max 30.3209, expressed in 32 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
155894	0.0483	17
155893	0.0375	12
155891	0.0273	7

Top tissues by expression

251 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	92.30	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.35	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.68	gold quality
tendon of biceps brachii	UBERON:0008188	79.64	silver quality
parotid gland	UBERON:0001831	78.03	gold quality
pancreatic ductal cell	CL:0002079	75.94	silver quality
transverse colon	UBERON:0001157	74.96	gold quality
rectum	UBERON:0001052	74.72	gold quality
vermiform appendix	UBERON:0001154	74.14	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	73.53	gold quality
lower esophagus mucosa	UBERON:0035834	71.65	gold quality
caecum	UBERON:0001153	70.95	gold quality
right hemisphere of cerebellum	UBERON:0014890	70.68	gold quality
nasal cavity epithelium	UBERON:0005384	70.46	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	70.44	gold quality
cortical plate	UBERON:0005343	70.43	gold quality
cerebellar hemisphere	UBERON:0002245	70.36	gold quality
cerebellar cortex	UBERON:0002129	70.23	gold quality
cerebellum	UBERON:0002037	69.69	gold quality
colonic mucosa	UBERON:0000317	68.54	gold quality
medial globus pallidus	UBERON:0002477	68.51	gold quality
mucosa of sigmoid colon	UBERON:0004993	67.58	silver quality
small intestine Peyer’s patch	UBERON:0003454	67.34	gold quality
right lobe of liver	UBERON:0001114	67.31	gold quality
left testis	UBERON:0004533	67.23	gold quality
upper arm skin	UBERON:0004263	67.20	gold quality
ganglionic eminence	UBERON:0004023	66.73	gold quality
putamen	UBERON:0001874	66.62	gold quality
globus pallidus	UBERON:0001875	66.57	gold quality
right testis	UBERON:0004534	66.48	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.22

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, JUN

miRNA regulators (miRDB)

2 targeting NOXO1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6826-3P	98.19	66.32	1153
HSA-MIR-6847-5P	97.93	66.74	1808

Literature-anchored findings (GeneRIF, showing 18)

• NOXO1 and NOXA1 activate Nox1 without the need for agonist activation, and this is mediated in part by binding of the NOXO1 PX domain to membrane lipids. (PMID:14617635)
• NOXO1, p47phox, and p67phox regulate Nox3 (PMID:15181005)
• Data suggest different tissue localizations and functions for NOXO1beta and NOXO1gamma in regulating Nox family members. (PMID:15949904)
• These results suggest that the formation of the complex consisting of Nox1, betaPix, and NoxO1 is likely to be a critical step in EGF-induced ROS generation. (PMID:16329988)
• This study shows the expression of alternatively spliced transcripts of the NOXO1 gene and the roles of the protein products in the activation of Nox oxidases. (PMID:16911517)
• These findings suggest that Nox activation involves a conformational change leading to disruption of the bis-SH3-PRR interaction in Noxo1. (PMID:17126813)
• The first quantitative characterization of the interactions made between the cytosolic regulators NOXO1 and NOXA1 and membrane-bound p22(phox), is presented. (PMID:20454568)
• The backbone assignments of NOXO1beta PX are studied using NMR. (PMID:21188560)
• Surface plasmon resonance experiments identify PtdIns(4,5)P(2) and PtdIns(3,4,5)P(3) as preferred targets of NOXO1beta PX. (PMID:22342885)
• Phorbol myristate acetate stimulates NOXO1 phosphorylation in a transfected human embryonic kidney (HEK) 293 epithelial cell model via protein kinase C and identify Ser-154 as the major phosphorylated site. (PMID:23322165)
• Phosphorylation of Thr341 allows Noxo1 to sufficiently interact with Noxa1, an interaction that participates in Nox1 activation (PMID:23957209)
• TNF-alpha/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells. (PMID:23975421)
• Data from pull-down assay between the Noxo1 and Noxa1 showed that the SH3 domains (Noxa1) is responsible for interaction with Noxo1 C-terminal tail harboring proline rich region. (PMID:28625920)
• PEDF protects human glomerular mesangial cells from diabetes-derived oxidative stress via NOXO1- iNOS suppression. (PMID:28944893)
• Tyrosine kinase substrate (Tks) proteins, analogous to the related proteins p47(phox), p40(phox) and NoxO1, also facilitate local generation of reactive oxygen species (ROS), which aid in signaling at invadopodia and/or podosomes to promote their activity. As their name suggests, Tks adaptor proteins are substrates for tyrosine kinases, especially Src. [review] (PMID:29311151)
• CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression. (PMID:34742871)
• Overexpression of a Novel Noxo1 Mutant Increases Ros Production and Noxo1 Relocalisation. (PMID:36902094)
• DNA methylation of ICAM4 and NOXO1 participate in the formation of uterine fibroids via regulating immune cell infiltration. (PMID:38015525)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	noxo1a	ENSDARG00000041294
danio_rerio	noxo1b	ENSDARG00000056374
mus_musculus	Noxo1	ENSMUSG00000019320
rattus_norvegicus	Noxo1	ENSRNOG00000025117

Paralogs (3): SH3PXD2A (ENSG00000107957), NCF1 (ENSG00000158517), SH3PXD2B (ENSG00000174705)

Protein

Protein identifiers

NADPH oxidase organizer 1 — Q8NFA2 (reviewed: Q8NFA2)

Alternative names: NADPH oxidase regulatory protein, Nox organizer 1, Nox-organizing protein 1, SH3 and PX domain-containing protein 5

All UniProt accessions (2): Q8NFA2, H3BN18

UniProt curated annotations — full annotation on UniProt →

Function. Constitutively potentiates the superoxide-generating activity of NOX1 and NOX3 and is required for the biogenesis of otoconia/otolith, which are crystalline structures of the inner ear involved in the perception of gravity. Isoform 3 is more potent than isoform 1 in activating NOX3. Together with NOXA1, may also substitute to NCF1/p47phox and NCF2/p67phox in supporting the phagocyte NOX2/gp91phox superoxide-generating activity.

Subunit / interactions. Interacts with NOX1, NOXA1, CYBA/p22phox and NCF2/p67phox. Interacts with SH3PXD2A and SH3PXD2B.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in testis, small and large intestines, liver, kidney and pancreas. Isoform 3 is mainly expressed in colon. Isoform 1 is preferentially expressed in testis.

Domain organisation. The PX domain mediates lipid-binding, localization to the plasma membrane and is required for NOX1 activation. The SH3 domains mediate interaction with CYBA/p22phox. Also mediates intramolecular interaction with the proline-rich region.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8NFA2-1	1, NOXO1gamma	yes
Q8NFA2-2	2, NOXO1delta
Q8NFA2-3	3, NOXO1beta
Q8NFA2-4	4, NOXO1alpha

RefSeq proteins (4): NP_001254650, NP_653204, NP_751907, NP_751908 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001452	SH3_domain	Domain
IPR001683	PX_dom	Domain
IPR035758	NoxO1_SH3_2	Domain
IPR036028	SH3-like_dom_sf	Homologous_superfamily
IPR036871	PX_dom_sf	Homologous_superfamily
IPR051228	NADPH_Oxidase/PX-Domain	Family

Pfam: PF00018

UniProt features (26 total): strand 6, helix 6, mutagenesis site 5, domain 3, region of interest 2, splice variant 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2L73	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NFA2-F1	64.67	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (5):

Position	Phenotype
202	loss of ability to activate nox3 and interact with cyba. induces interaction with noxa1 in vitro.
274	induces interaction with noxa1 in vitro.
332	loss of intramolecular interaction.
334	loss of intramolecular interaction.
40	loss of ability to activate nox1 associated with loss of lipid-binding and plasma membrane localization.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-5668599	RHO GTPases Activate NADPH Oxidases
R-HSA-9013149	RAC1 GTPase cycle
R-HSA-9013423	RAC3 GTPase cycle
R-HSA-9673324	WNT5:FZD7-mediated leishmania damping

MSigDB gene sets: 105 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, GOBP_REGULATION_OF_RESPIRATORY_BURST, BENPORATH_ES_WITH_H3K27ME3, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GOBP_SUPEROXIDE_METABOLIC_PROCESS, GOBP_REGULATION_OF_REACTIVE_OXYGEN_SPECIES_METABOLIC_PROCESS, GOBP_RESPIRATORY_BURST, GOBP_SUPEROXIDE_ANION_GENERATION, GOBP_EXTRACELLULAR_MATRIX_DISASSEMBLY, GOBP_HYDROGEN_PEROXIDE_METABOLIC_PROCESS, GOBP_REGULATION_OF_HYDROGEN_PEROXIDE_METABOLIC_PROCESS, GOBP_REACTIVE_OXYGEN_SPECIES_METABOLIC_PROCESS, GOCC_OXIDOREDUCTASE_COMPLEX, GOCC_MEMBRANE_PROTEIN_COMPLEX, GOCC_PLASMA_MEMBRANE_PROTEIN_COMPLEX

GO Biological Process (5): regulation of hydrogen peroxide metabolic process (GO:0010310), extracellular matrix disassembly (GO:0022617), superoxide anion generation (GO:0042554), regulation of respiratory burst (GO:0060263), superoxide metabolic process (GO:0006801)

GO Molecular Function (6): phospholipid binding (GO:0005543), superoxide-generating NADPH oxidase activator activity (GO:0016176), enzyme binding (GO:0019899), phosphatidylinositol binding (GO:0035091), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (4): cytoplasm (GO:0005737), plasma membrane (GO:0005886), NADPH oxidase complex (GO:0043020), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
RHO GTPase cycle	2
RHO GTPase Effectors	1
Killing mechanisms	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cellular anatomical structure	2
hydrogen peroxide metabolic process	1
regulation of reactive oxygen species metabolic process	1
cellular component disassembly	1
extracellular matrix organization	1
superoxide metabolic process	1
regulation of metabolic process	1
respiratory burst	1
reactive oxygen species metabolic process	1
lipid binding	1
enzyme activator activity	1
superoxide-generating NADPH oxidase activity	1
protein binding	1
anion binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
plasma membrane protein complex	1
oxidoreductase complex	1

Protein interactions and networks

STRING

950 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NOXO1	NOXA1	Q86UR1	999
NOXO1	NCF2	P19878	999
NOXO1	NOX1	Q9Y5S8	999
NOXO1	CYBA	P13498	998
NOXO1	NCF4	Q15080	995
NOXO1	NOX3	Q9HBY0	992
NOXO1	NCF1	P14598	988
NOXO1	CYBB	P04839	983
NOXO1	RAC2	P15153	969
NOXO1	AKT1	P31749	865
NOXO1	TRADD	Q15628	851
NOXO1	NOX5	Q96PH1	793
NOXO1	DUOX1	Q9NRD9	767
NOXO1	NOX4	Q9NPH5	733
NOXO1	RFK	Q969G6	702

IntAct

10 interactions, top by confidence:

A	B	Type	Score
CYBA	NOXO1	psi-mi:“MI:0407”(direct interaction)	0.710
NOXO1	CYBA	psi-mi:“MI:0407”(direct interaction)	0.710
NOXA1	NOXO1	psi-mi:“MI:0407”(direct interaction)	0.590
NOXO1	NOXO1	psi-mi:“MI:0407”(direct interaction)	0.440
NOXO1	SOD1	psi-mi:“MI:0914”(association)	0.350
NOXO1	HSPA8	psi-mi:“MI:0914”(association)	0.350
NOXO1	TUSC2	psi-mi:“MI:0914”(association)	0.350

BioGRID (21): NOXO1 (Affinity Capture-MS), NOXO1 (Reconstituted Complex), ARHGAP8 (Affinity Capture-MS), MAP1S (Affinity Capture-MS), MAP1B (Affinity Capture-MS), HSPA8 (Affinity Capture-MS), HSPA2 (Affinity Capture-MS), HSPE1 (Affinity Capture-MS), BAG5 (Affinity Capture-MS), STUB1 (Affinity Capture-MS), PASK (Affinity Capture-MS), TUSC2 (Affinity Capture-MS), LMNA (Affinity Capture-MS), PSMG3 (Affinity Capture-MS), NOXO1 (Affinity Capture-Western)

ESM2 similar proteins: A3R064, A7MBB8, B2RYG7, D3ZZN9, E1BDF2, O60496, O70469, O94989, O95153, P97465, P97680, P98077, Q13671, Q14B98, Q1RMU7, Q3MIN7, Q3UR97, Q3UYI5, Q494U1, Q4QQV2, Q58EX7, Q5EA84, Q5FWH6, Q6ICB4, Q6PGG2, Q6ZW31, Q7L591, Q7TNF8, Q8BH49, Q8BWA8, Q8IW93, Q8IYJ3, Q8N878, Q8NAG6, Q8NFA2, Q91WA6, Q921Q7, Q92502, Q969H4, Q969T3

Diamond homologs: Q62662, Q8NFA2, Q8VCM2, O89032

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
PRKCA	up-regulates	NOXO1	phosphorylation
NOXO1	“up-regulates activity”	NOXA1	relocalization
PKC	“up-regulates activity”	NOXO1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	84
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1205 predictions. Top by Δscore:

Variant	Effect	Δscore
16:1979419:GCGTA:G	donor_loss	1.0000
16:1979420:CGTAC:C	donor_loss	1.0000
16:1979421:GTACC:G	donor_loss	1.0000
16:1979422:TACCT:T	donor_loss	1.0000
16:1979423:A:C	donor_loss	1.0000
16:1979424:C:G	donor_loss	1.0000
16:1979789:CCG:C	donor_gain	1.0000
16:1979797:C:CA	donor_gain	1.0000
16:1979840:T:TA	donor_gain	1.0000
16:1979991:CCCTA:C	donor_loss	1.0000
16:1979992:CCTA:C	donor_loss	1.0000
16:1979993:CTA:C	donor_loss	1.0000
16:1979994:TAC:T	donor_loss	1.0000
16:1979995:A:AT	donor_loss	1.0000
16:1979996:CCT:C	donor_loss	1.0000
16:1980934:CTCA:C	donor_loss	1.0000
16:1980935:TCA:T	donor_loss	1.0000
16:1980936:CA:C	donor_loss	1.0000
16:1980937:ACCTT:A	donor_loss	1.0000
16:1979346:GTACC:G	acceptor_loss	0.9900
16:1979349:CCTG:C	acceptor_loss	0.9900
16:1979350:CT:C	acceptor_loss	0.9900
16:1979351:T:A	acceptor_loss	0.9900
16:1979543:C:G	acceptor_loss	0.9900
16:1979544:T:A	acceptor_loss	0.9900
16:1979669:T:TA	donor_gain	0.9900
16:1979813:C:A	donor_gain	0.9900
16:1979899:CCAGC:C	acceptor_gain	0.9900
16:1979900:CAGC:C	acceptor_gain	0.9900
16:1979900:CAGCC:C	acceptor_gain	0.9900

AlphaMissense

2326 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:1979860:A:C	F215L	0.988
16:1979860:A:T	F215L	0.988
16:1979862:A:G	F215L	0.988
16:1979861:A:G	F215S	0.987
16:1979865:A:G	W214R	0.980
16:1979865:A:T	W214R	0.980
16:1979899:C:A	W202C	0.978
16:1979899:C:G	W202C	0.978
16:1981014:A:C	F24L	0.978
16:1981014:A:T	F24L	0.978
16:1981016:A:G	F24L	0.978
16:1979898:A:G	W203R	0.977
16:1979898:A:T	W203R	0.977
16:1979901:A:G	W202R	0.976
16:1979901:A:T	W202R	0.976
16:1980076:G:C	F174L	0.975
16:1980076:G:T	F174L	0.975
16:1980078:A:G	F174L	0.975
16:1980414:G:C	F123L	0.975
16:1980414:G:T	F123L	0.975
16:1980416:A:G	F123L	0.975
16:1980998:A:G	W30R	0.974
16:1980998:A:T	W30R	0.974
16:1980046:A:C	F184L	0.972
16:1980046:A:T	F184L	0.972
16:1980048:A:G	F184L	0.972
16:1980711:G:C	F56L	0.972
16:1980711:G:T	F56L	0.972
16:1980713:A:G	F56L	0.972
16:1980951:G:C	F45L	0.970

dbSNP variants (sampled 300 via entrez): RS1000521284 (16:1982785 C>T), RS1001437970 (16:1982394 G>A,C), RS1002240340 (16:1978958 C>G,T), RS1002509390 (16:1982895 G>A), RS1002841948 (16:1979724 T>G), RS1003626090 (16:1981566 C>G,T), RS1005019398 (16:1982203 C>T), RS1005615981 (16:1983322 T>A,G), RS1005823288 (16:1978974 G>A,T), RS1006132607 (16:1980002 G>A,T), RS1007214113 (16:1982345 CCTT>C), RS1007837378 (16:1980852 G>T), RS1008102961 (16:1980211 G>A), RS1008445243 (16:1980430 G>A,C), RS1008587307 (16:1978782 C>G,T)

Disease associations

OMIM: gene MIM:611256 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90002404_333	Red cell distribution width	2.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5291596 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.70	Kd	2	nM	CHEMBL5271171

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-[2-[[1-[3-[2-[2-[2-[2-[5-[(3aR,4R,6aS)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoyl]piperidin-4-yl]methylamino]phenyl]benzamide	1955023: Inhibition of 6His tagged NOXO1 (149 to 286 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as apparent dissociation constant at 800 uM by isothermal titration calorimetry	kd	0.0020	uM

CTD chemical–gene interactions

21 total (human), top 21 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Vehicle Emissions	decreases expression, decreases reaction	2
Benzo(a)pyrene	decreases expression, decreases methylation	2
Particulate Matter	decreases expression, decreases reaction, increases abundance, increases expression	2
methyleugenol	decreases expression	1
potassium perchlorate	decreases expression	1
abrine	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
jinfukang	decreases expression	1
prothioconazole	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Cisplatin	decreases expression	1
Phthalic Acids	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Tetradecanoylphorbol Acetate	affects reaction, increases expression	1
Dronabinol	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases expression	1
Copper Sulfate	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5259024	Binding	Inhibition of 6His tagged NOXO1 (149 to 286 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as apparent dissociation constant at 800 uM by isothermal titration calorimetry	Identification of a Noxo1 inhibitor by addition of a polyethylene glycol chain. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.